Antifungal activity of amphotericin B, fluconazole, and voriconazole in an in vitro model of Candida catheter-related bloodstream infection
about
Bench-to-bedside review: therapeutic management of invasive candidiasis in the intensive care unitAntifungal lock therapyAnalysis of Candida albicans mutants defective in the Cdk8 module of mediator reveal links between metabolism and biofilm formationCandida biofilms: an update.In vitro growth and analysis of Candida biofilms.Candida albicans Niche Specialization: Features That Distinguish Biofilm Cells from Commensal Cells.Development and validation of an in vivo Candida albicans biofilm denture model.Towards non-invasive monitoring of pathogen-host interactions during Candida albicans biofilm formation using in vivo bioluminescence.Quinacrine inhibits Candida albicans growth and filamentation at neutral pH.Histatin 5 resistance of Candida glabrata can be reversed by insertion of Candida albicans polyamine transporter-encoding genes DUR3 and DUR31.A small subpopulation of blastospores in candida albicans biofilms exhibit resistance to amphotericin B associated with differential regulation of ergosterol and beta-1,6-glucan pathway genes.Putative role of beta-1,3 glucans in Candida albicans biofilm resistance.Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic modelCandida infections of medical devices.Species-specific differences in the susceptibilities of biofilms formed by Candida bloodstream isolates to echinocandin antifungals.Novel modes of antifungal drug administration.Combination treatment of invasive fungal infections.Fungal Biofilms: In Vivo Models for Discovery of Anti-Biofilm DrugsEfficacy of surface-generated nitric oxide against Candida albicans adhesion and biofilm formation.The Role of Antifungals against Candida Biofilm in Catheter-Related Candidemia.Development and characterization of an in vivo central venous catheter Candida albicans biofilm model.In vitro pharmacodynamic models to determine the effect of antibacterial drugs.Oral mucositis caused by Candida glabrata biofilms: failure of the concomitant use of fluconazole and ascorbic acid.Pharmacokinetic evaluation of fluconazole in critically ill patients.Recent insights into Candida albicans biofilm resistance mechanismsFuture directions for anti-biofilm therapeutics targeting Candida.Elimination of Bloodstream Infections Associated with Candida albicans Biofilm in Intravascular Catheters.Medically important fungi respond to azole drugs: an update.The Effectiveness of Voriconazole in Therapy of Candida glabrata's Biofilms Oral Infections and Its Influence on the Matrix Composition and Gene Expression.Pathogenic factors in Candida biofilm-related infectious diseases.A brief history of antibiotics and select advances in their synthesis.Penetration of Candida biofilms by antifungal agents.In vitro pharmacodynamics of rapid versus continuous infusion of amphotericin B deoxycholate against Candida species in the presence of human serum albumin.Serum voriconazole levels following administration via percutaneous jejunostomy tube.Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit.Use of voriconazole in candida retinitis.Antibacterial activity of linezolid and vancomycin in an in vitro pharmacodynamic model of gram-positive catheter-related bacteraemia.(B1) Candida and mycotic infections.Pore formers promoted release of an antifungal drug from functionalized polyurethanes to inhibit Candida colonization.The Interface between Fungal Biofilms and Innate Immunity.
P2860
Q21194915-DB35CEA5-C43F-456A-9604-976B3D505242Q27025682-07864FB7-6631-4402-BAE8-E82734B1E902Q28543481-8A994A54-E763-425A-9008-6425603B820EQ30475833-53B6568E-D524-403D-A593-254FAD3F96ACQ33404034-B9DA7A0C-6796-42E6-9EAA-C970E7133263Q33603993-DFC857B2-8F88-4C16-B5F2-12BA52F068BAQ34119405-81279D0A-51C9-4AC7-BCE9-6FE815E14000Q34376059-7BC71BBC-7AEC-4566-A92E-39B68952CB2EQ34597683-47F53B71-59C8-4A84-AD51-60FD4F203945Q34684434-3E694CFD-2114-4199-A23B-6BDDA8BCED77Q35127891-69E947F7-A419-4641-BE1B-9F38A9D7D74FQ35635952-4CD38804-F957-4F96-862E-DCC067B476C8Q35666627-7E82E8F6-665C-4EAE-ADB7-727B5B0BC950Q35745818-24D37264-4D36-4634-92F0-22D8E110F501Q35758901-06491A12-E26B-41E5-BDCE-BFC728B81475Q35842520-F8C22B07-21DA-4040-AE86-DD7ADA19EC5DQ36011378-39132A33-7C77-4D61-8EE9-7E10427223B9Q36089061-5EDA377C-19CA-42AB-9619-251A19999A4CQ36593530-F1875894-3B98-4548-A61B-66D34C451542Q36683547-3EF4D959-6257-4931-9C0A-F8EB2F457055Q37523933-FDF84068-7382-49F0-A2FB-B2318D225FBAQ37660762-9ADD78B7-F2C3-41EA-85CB-755A4FA9F7DFQ37713936-A042BF2D-0A5F-4114-BECC-FA3E389A8E65Q37924819-F894B35B-0E81-4B2F-8052-6F50B67752DFQ38131290-9EC68614-44D8-4E2B-A5B4-6B4B461D390DQ38186068-11838792-0E80-49FA-A4BB-B3EC08DFEB69Q38541374-B629681B-0959-4992-8751-8235C94D67AFQ38559208-D573880B-0ACA-4569-ACFD-15AE2F3541ABQ38691273-AFC12987-FB12-498B-98F3-55DEBF0A108EQ38807782-E8172154-8B14-4F1A-9DC4-1EFEFDA1A45AQ39414195-C726F110-1720-4426-A70F-20713D101F7AQ39955289-45F5ACC1-5661-4F5B-97C8-C0E4D9FBFCCFQ42676999-99CE442A-E727-47E7-9495-986C9D5BE18EQ42949323-E54CB314-4B94-48CE-8622-CA832DE5BC26Q43737173-790E79EA-0292-4087-9DBE-F8BF23F72B49Q44857273-9D1C5004-D1D6-408B-97E8-BFD02C0E5467Q46425775-D76530B4-913B-4468-B86C-D8505E9169E6Q46885843-F605B17E-010E-4B87-A0AE-0B78900C8188Q46944691-0071258F-5742-4F64-8A45-BC02F85A9750Q49203638-52AE01D5-F127-4239-99C4-97014B02FC81
P2860
Antifungal activity of amphotericin B, fluconazole, and voriconazole in an in vitro model of Candida catheter-related bloodstream infection
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Antifungal activity of amphote ...... -related bloodstream infection
@ast
Antifungal activity of amphote ...... -related bloodstream infection
@en
Antifungal activity of amphote ...... -related bloodstream infection
@nl
type
label
Antifungal activity of amphote ...... -related bloodstream infection
@ast
Antifungal activity of amphote ...... -related bloodstream infection
@en
Antifungal activity of amphote ...... -related bloodstream infection
@nl
prefLabel
Antifungal activity of amphote ...... -related bloodstream infection
@ast
Antifungal activity of amphote ...... -related bloodstream infection
@en
Antifungal activity of amphote ...... -related bloodstream infection
@nl
P2093
P2860
P1476
Antifungal activity of amphote ...... -related bloodstream infection
@en
P2093
Dimitrios P Kontoyiannis
Issam I Raad
Rabih O Darouiche
Randall A Prince
P2860
P304
P356
10.1128/AAC.46.11.3499-3505.2002
P407
P577
2002-11-01T00:00:00Z